Alice Larsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alice Larsson has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Abdellah Tebani
Normandie Univ, UNIROUEN, AIMS, SysMedLab, CHU Rouen, Department of Metabolic Biochemistry, Referral Center for Lysosomal Diseases, Filière G2M, 76000 Rouen, France
1 shared publication - Alexander Hoetink
Princess Màxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
1 shared publication - Allan Zhao
Department of Physiology and Pharmacology, Karolinska Institutet
1 shared publication - Alwin D. R. Huitema
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publication - Arturo Reyes Palomares
Laboratory of Translational Fertility Preservation, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
1 shared publication - Britt Edén Engström
Department of Medical Sciences, Endocrinology and Mineral Metabolism, Uppsala University, Uppsala, Sweden
1 shared publication
Latest Publications
- Open Access
- 5 May 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (8) , 1-12
Prestin as a potential biomarker for cochlear injury: Current evidence and future directions
Purpose Prestin has been identified as a potential biomarker for cochlear damage and consequent ototoxicity. Although several preclinical and clinical studies have investigated prestin, a comprehensive overview of the evidence regarding its diagnostic value across different types of auditory damage and its use for cancer treatment-related ototoxicity is currently lacking. Methods A structured literature review, based on a systematic PubMed search, was conducted to summarize preclinical and clinical studies that evaluated serum and/or plasma prestin levels in association with cochlear damage. Studies were categorized by etiology, moment of biomarker assessment, and correlation with functional hearing outcomes. Results Twenty-one studies (six animal, 15 human) were included. In animal models, prestin levels increased within hours to days after cochlear injury. Clinical studies showed elevated prestin levels within 30 days after acute damage, due to cisplatin exposure, noise exposure, or surgery. Higher prestin levels correlated with elevated hearing thresholds in six studies, whereas findings were more variable in age-related or chronic hearing loss. So far, no pediatric populations have been studied, and reference values or diagnostic thresholds for prestin are lacking. Conclusion Prestin shows potential for use as a biomarker for acute cochlear damage, with time-dependent patterns observed in both animal and human studies. However, heterogeneity in study design, patient populations, and measurement methods limits current general conclusions and recommendations for its use in the clinical field. Further standardized and longitudinal studies, including pediatric and cancer-survivor cohorts, are needed to determine its clinical utility.
- 5 May 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (8) , 1-12
Open AccessPrestin as a potential biomarker for cochlear injury: Current evidence and future directions
Purpose Prestin has been identified as a potential biomarker for cochlear damage and consequent ototoxicity. Although several preclinical and clinical studies have investigated prestin, a comprehensive overview of the evidence regarding its diagnostic value across different types of auditory damage and its use for cancer treatment-related ototoxicity is currently lacking. Methods A structured literature review, based on a systematic PubMed search, was conducted to summarize preclinical and clinical studies that evaluated serum and/or plasma prestin levels in association with cochlear damage. Studies were categorized by etiology, moment of biomarker assessment, and correlation with functional hearing outcomes. Results Twenty-one studies (six animal, 15 human) were included. In animal models, prestin levels increased within hours to days after cochlear injury. Clinical studies showed elevated prestin levels within 30 days after acute damage, due to cisplatin exposure, noise exposure, or surgery. Higher prestin levels correlated with elevated hearing thresholds in six studies, whereas findings were more variable in age-related or chronic hearing loss. So far, no pediatric populations have been studied, and reference values or diagnostic thresholds for prestin are lacking. Conclusion Prestin shows potential for use as a biomarker for acute cochlear damage, with time-dependent patterns observed in both animal and human studies. However, heterogeneity in study design, patient populations, and measurement methods limits current general conclusions and recommendations for its use in the clinical field. Further standardized and longitudinal studies, including pediatric and cancer-survivor cohorts, are needed to determine its clinical utility.
- Open Access
- 30 January 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Mixed gangliocytoma-pituitary neuroendocrine tumour: clinical, immunohistochemical, and molecular genetic profiles in a series of four patients
The vast majority of tumours in the sellar region are pituitary neuroendocrine tumours, also called pituitary adenomas. Sellar gangliocytomas (GCs), benign tumours that originate from neuronal ganglionic cells, account for less than 1% of sellar tumours. Even rarer are mixed gangliocytoma-pituitary neuroendocrine tumours (GC-PitNET). These tumours are often associated with hormone hypersecretion, most commonly resulting in acromegaly. The histogenesis of mixed GC–PitNET is currently unclear. In this paper, we present comprehensive clinical, immunohistochemical, targeting enrichment next generation DNA sequencing, and genome-wide methylation data from four patients with mixed GC-PitNETs, three with acromegaly and one with Cushing’s disease. Transcriptomic data are also included for two of the patients. Our findings indicate that mixed GC-PitNETs have different clinical course, with the acromegaly patients showing greater resistance to pharmacological therapy, as well as different protein expression and molecular features compared to respective pure PitNETs. The transcriptomic data on two patients with somatotroph GC-PitNET show involvement of mitochondrial and ribosomal genes, suggesting a distinct gene expression pattern, in comparison with pure somatotroph tumours. Furthermore, the expression pattern of selected stem cell markers, mainly SOX9, supports a common origin of the neuroendocrine and ganglionic tumour components, suggesting the involvement of stem cells in tumorigenesis.
- 30 January 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Open AccessMixed gangliocytoma-pituitary neuroendocrine tumour: clinical, immunohistochemical, and molecular genetic profiles in a series of four patients
The vast majority of tumours in the sellar region are pituitary neuroendocrine tumours, also called pituitary adenomas. Sellar gangliocytomas (GCs), benign tumours that originate from neuronal ganglionic cells, account for less than 1% of sellar tumours. Even rarer are mixed gangliocytoma-pituitary neuroendocrine tumours (GC-PitNET). These tumours are often associated with hormone hypersecretion, most commonly resulting in acromegaly. The histogenesis of mixed GC–PitNET is currently unclear. In this paper, we present comprehensive clinical, immunohistochemical, targeting enrichment next generation DNA sequencing, and genome-wide methylation data from four patients with mixed GC-PitNETs, three with acromegaly and one with Cushing’s disease. Transcriptomic data are also included for two of the patients. Our findings indicate that mixed GC-PitNETs have different clinical course, with the acromegaly patients showing greater resistance to pharmacological therapy, as well as different protein expression and molecular features compared to respective pure PitNETs. The transcriptomic data on two patients with somatotroph GC-PitNET show involvement of mitochondrial and ribosomal genes, suggesting a distinct gene expression pattern, in comparison with pure somatotroph tumours. Furthermore, the expression pattern of selected stem cell markers, mainly SOX9, supports a common origin of the neuroendocrine and ganglionic tumour components, suggesting the involvement of stem cells in tumorigenesis.
- Open Access
- 15 March 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (4) , 1752-1772
Appropriate glycemic management protects the germline but not the uterine environment in hyperglycemia
Emerging evidence indicates that parental diseases can impact the health of subsequent generations through epigenetic inheritance. Recently, it was shown that maternal diabetes alters the metaphase II oocyte transcriptome, causing metabolic dysfunction in offspring. However, type 1 diabetes (T1D) mouse models frequently utilized in previous studies may be subject to several confounding factors due to severe hyperglycemia. This limits clinical translatability given improvements in glycemic control for T1D subjects. Here, we optimize a T1D mouse model to investigate the effects of appropriately managed maternal glycemic levels on oocytes and intrauterine development. We show that diabetic mice with appropriate glycemic control exhibit better long-term health, including maintenance of the oocyte transcriptome and chromatin accessibility. We further show that human oocytes undergoing in vitro maturation challenged with mildly increased levels of glucose, reflecting appropriate glycemic management, also retain their transcriptome. However, fetal growth and placental function are affected in mice despite appropriate glycemic control, suggesting the uterine environment rather than the germline as a pathological factor in developmental programming in appropriately managed diabetes.
- 15 March 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (4) , 1752-1772
Open AccessAppropriate glycemic management protects the germline but not the uterine environment in hyperglycemia
Emerging evidence indicates that parental diseases can impact the health of subsequent generations through epigenetic inheritance. Recently, it was shown that maternal diabetes alters the metaphase II oocyte transcriptome, causing metabolic dysfunction in offspring. However, type 1 diabetes (T1D) mouse models frequently utilized in previous studies may be subject to several confounding factors due to severe hyperglycemia. This limits clinical translatability given improvements in glycemic control for T1D subjects. Here, we optimize a T1D mouse model to investigate the effects of appropriately managed maternal glycemic levels on oocytes and intrauterine development. We show that diabetic mice with appropriate glycemic control exhibit better long-term health, including maintenance of the oocyte transcriptome and chromatin accessibility. We further show that human oocytes undergoing in vitro maturation challenged with mildly increased levels of glucose, reflecting appropriate glycemic management, also retain their transcriptome. However, fetal growth and placental function are affected in mice despite appropriate glycemic control, suggesting the uterine environment rather than the germline as a pathological factor in developmental programming in appropriately managed diabetes.